Retrospective Assessment of Referral of a Major Trauma Patient
Launched by HÔPITAL NOVO · Aug 9, 2024
Trial Information
Current as of September 08, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how major trauma patients in the Val d'Oise area are referred to the right trauma centers for their care. The goal is to understand if these patients receive the proper treatment and to evaluate how effectively emergency services are assessing their needs during critical situations.
To be eligible for this study, participants need to be adults aged 65 or older who have experienced a serious injury and are being helped by the local emergency services (SAMU 95) between January 1, 2023, and December 31, 2023. Certain medical indicators, like a low level of consciousness or significant blood loss, must also be present to qualify. If you take part in this study, you won’t have to do anything extra; researchers will review information from your emergency care to improve future trauma treatment in the area. It's important to note that those who unfortunately pass away at the scene or are treated outside the designated area won’t be included in the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria :
- • Between the 1st January 2023 and the 31th December 2023
- • Regulated by SAMU 95 with suspected major trauma
- • Sending an MCIU
- • At least 1 Vittel criterion\*
- Exclusion Criteria :
- • Death on site
- • Care by an MICU team outside the 95
- • Minor patients and legal protection
- • Transport refusals
- * Vittel criterion :
- • • Physiological variables : Glasgow score \< 13 Systolic blood pressure \< 90 mmHg O2 saturation \< 90%
- • • Elements of kinetics : Ejection from a vehicle Other passenger killed in the same vehicle Fall \> 6 metres Victim thrown or crushed Overall assessment (deformation of the vehicle, estimated speed, absence of helmet, absence of seatbelt) Blast
- • • Anatomical lesions : Penetrating trauma to the head, neck, thorax, abdomen, pelvis, arm or thigh Flail chest Severe burn, smoke inhalation Pelvic fracture Suspected spinal cord injury Amputation of wrist, ankle or above Acute limb ischaemia
- • • Pre-hospital resuscitation : Assisted ventilation Filling \> 1000 ml with colloids Catecholamines Inflated shock-proof trousers
- • • Medical context (to be assessed) : Age \> 65 Cardiac or coronary insufficiency Respiratory insufficiency Pregnancy (2nd and 3rd trimesters) Blood crase disorders
About Hôpital Novo
Hôpital Novo is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative studies and rigorous scientific methodologies. With a strong emphasis on collaboration and ethical practices, Hôpital Novo partners with healthcare professionals and institutions to conduct high-quality clinical trials across various therapeutic areas. Their commitment to patient safety, data integrity, and regulatory compliance ensures that all research initiatives are conducted to the highest standards, ultimately contributing to the development of new treatments and therapies that enhance healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pontoise, , France
Patients applied
Trial Officials
Fabrice LOUVET
Principal Investigator
Hôpital NOVO
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported